48Q0 Stock Chart & Stats
€4.90
€0.00(0.00%)
At close: 4:00 PM EDT
€4.90
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€4.90 - €5.08
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€325.51M
Enterprise Value€365.11
Total Cash (Recent Filing)€233.72M
Total Debt (Recent Filing)€77.25M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.54
Shares Outstanding94,319,695
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)4.82
P/FCF Ratio-1.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.97Price Target Upside103.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.62
Revenue Forecast (FY)€8.39M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Balance SheetSubstantial debt reduction and a sizable equity base materially improve financial flexibility. With ~0.00x debt-to-equity and stable assets, the company is better positioned to fund clinical programs, absorb setbacks, and access non-debt financing without near-term solvency pressure.
High Gross MarginsSustained high gross margins indicate favorable product economics and scalable cost structure for drug supply. If commercialization expands, these margins can support operating leverage and improve profitability over time, making eventual margin expansion more achievable.
Approved Product Plus Phase 3 ProgramRegulatory approval for a rare-disease indication provides a commercial foothold and validates the CXCR4 approach. Concurrent Phase 3 development expands potential label and patient population, offering durable revenue upside and de-risking clinical value versus purely preclinical assets.
Bears Say
Persistent Heavy Cash BurnConsistent substantial cash outflows create ongoing funding requirements and shorten runway absent revenue growth or financing. This structural cash burn increases reliance on external capital, raises dilution risk, and constrains long-term R&D and commercial investments unless costs or revenues change materially.
Highly Volatile RevenueLarge swings and a steep TTM revenue decline undermine predictability of commercial traction and complicate budgeting for sales, manufacturing, and development. Structural revenue volatility signals concentration or timing dependency, making sustainable scaling and forecasting more difficult over the medium term.
Dilution Risk From Equity Plan ExpansionExpanded equity awards help attract and retain talent but increase potential share count at a time of heavy cash burn and funding needs. This structural dilution risk can erode per-share economics and investor returns if equity is used repeatedly to fund operations or compensate for ongoing losses.
X4 Pharmaceuticals News
48Q0 FAQ
What was X4 Pharmaceuticals Inc’s price range in the past 12 months?
X4 Pharmaceuticals Inc lowest stock price was €4.90 and its highest was €5.08 in the past 12 months.
What is X4 Pharmaceuticals Inc’s market cap?
X4 Pharmaceuticals Inc’s market cap is €325.51M.
When is X4 Pharmaceuticals Inc’s upcoming earnings report date?
X4 Pharmaceuticals Inc’s upcoming earnings report date is Oct 29, 2026 which is in 84 days.
How were X4 Pharmaceuticals Inc’s earnings last quarter?
X4 Pharmaceuticals Inc released its earnings results on May 06, 2026. The company reported -€0.139 earnings per share for the quarter, beating the consensus estimate of -€0.173 by €0.035.
Is X4 Pharmaceuticals Inc overvalued?
According to Wall Street analysts X4 Pharmaceuticals Inc’s price is currently Undervalued.
Does X4 Pharmaceuticals Inc pay dividends?
X4 Pharmaceuticals Inc does not currently pay dividends.
What is X4 Pharmaceuticals Inc’s EPS estimate?
X4 Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does X4 Pharmaceuticals Inc have?
X4 Pharmaceuticals Inc has 94,319,695 shares outstanding.
What happened to X4 Pharmaceuticals Inc’s price movement after its last earnings report?
X4 Pharmaceuticals Inc reported an EPS of -€0.139 in its last earnings report, beating expectations of -€0.173. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in DE:48Q0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
X4 Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€9.97 (103.43% Upside)
€9.97 (103.43% Upside)
Blogger Sentiment
Bullish
DE:48Q0 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €94.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
107.89%
Trailing 12-Months
Company Description
X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
48Q0 Stock 12 Month Forecast
Average Price Target
€9.97
▲(103.43% Upside)